Eli Lilly and Company
LLYHealthcare
$1,026.11
-2.46%
Price History (1 Year)
Market Cap
$968.0B
P/E Ratio
44.8x
P/B Ratio
36.37x
EV/EBITDA
35.8x
ROE
77.8%
FCF Yield
0.9%
Div. Yield
0.62%
DCF Value
$1855.94
Undervalued vs DCF
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025-12-31 | $19.29B | $6.64B | $7.41 |
| 2025-09-30 | $17.60B | $5.58B | $6.22 |
| 2025-06-30 | $15.56B | $5.66B | $6.30 |
| 2025-03-31 | $12.73B | $2.76B | $3.07 |
AI Analysis
LLY: Foundayo Approval Crowns the GLP-1 King
- •FDA approved Lilly's oral weight-loss drug Foundayo today — the first oral GLP-1 for obesity, giving Lilly a 12-18 month competitive moat.
- •FY2025 revenue hit $65.2 billion with Q4 gross margins of 85%, but free cash flow lagged at $0.75/share due to massive manufacturing capex.
- •At 42x earnings and $913 billion market cap, the stock prices in flawless execution — wait for the April 30 earnings report before adding new positions.
Read full analysis →
Healthcare Peers
Related Articles
Data provided by Financial Modeling Prep. AI analysis generated by Claude. This is not financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.